Aileron Therapeutics Inc.

1.21+0.0200+1.68%Vol 1.17M1Y Perf 118.95%
Apr 16th, 2021 16:00 DELAYED
BID1.17 ASK1.20
Open1.18 Previous Close1.19
Pre-Market- After-Market-
 - -  - -%
Target Price
2.00 
Analyst Rating
Strong Buy 1.00
Potential %
65.29 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/100/100 
Growth Ranking
★★+ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/100/100 
Income Ranking
 —    -
Market Cap109.16M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
37.31 
Earnings Date
10th May 2021

Today's Price Range

1.151.24

52W Range

0.46002.47

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-9.70%
1 Month
-29.24%
3 Months
-34.24%
6 Months
-36.65%
1 Year
118.95%
3 Years
-82.69%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALRN1.210.02001.68
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.11-0.12-9.09
Q03 2020-0.10-0.13-30.00
Q02 2020-0.16-0.1412.50
Q01 2020-0.20-0.24-20.00
Q04 2019--0.26-
Q03 2019-0.24-0.28-16.67
Q02 2019-0.23-0.26-13.04
Q01 2019-0.46-0.49-6.52
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.0554.55Positive
6/2021 QR-0.0838.46Positive
12/2021 FY-0.3134.04Positive
12/2022 FY-0.469.80Positive
Next Report Date10th May 2021
Estimated EPS Next Report-0.05
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1.17M
Shares Outstanding90.21M
Trades Count3.31K
Dollar Volume3.06M
Avg. Volume3.89M
Avg. Weekly Volume1.33M
Avg. Monthly Volume1.33M
Avg. Quarterly Volume2.64M

Aileron Therapeutics Inc. (NASDAQ: ALRN) stock closed at 1.21 per share at the end of the most recent trading day (a 1.68% change compared to the prior day closing price) with a volume of 1.18M shares and market capitalization of 109.16M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 13 people. Aileron Therapeutics Inc. CEO is Manuel C. Alves Aivado.

The one-year performance of Aileron Therapeutics Inc. stock is 118.95%, while year-to-date (YTD) performance is 16.35%. ALRN stock has a five-year performance of %. Its 52-week range is between 0.46 and 2.47, which gives ALRN stock a 52-week price range ratio of 37.31%

Aileron Therapeutics Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 10.53, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -93.69%, a ROC of -102.84% and a ROE of -142.79%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Aileron Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. Aileron Therapeutics Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Aileron Therapeutics Inc. is Strong Buy (1), with a target price of $2, which is +65.29% compared to the current price. The earnings rating for Aileron Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aileron Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aileron Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 28.47, ATR14 : 0.16, CCI20 : -136.72, Chaikin Money Flow : 0.01, MACD : -0.15, Money Flow Index : 20.94, ROC : -11.68, RSI : 38.49, STOCH (14,3) : 16.22, STOCH RSI : 0.67, UO : 48.55, Williams %R : -83.78), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aileron Therapeutics Inc. in the last 12-months were: Josef H. Von Rickenbach (Buy at a value of $249 999), Muneer A. Satter (Buy at a value of $18 040 000), Reinhard J. Ambros (Buy at a value of $7 076)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aileron Therapeutics Inc.

Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing and commercializing a novel class of therapeutics called stapled peptides. The company's lead product candidate, ALRN-6924, targets the tumor suppressor p53 for the treatment of a wide variety of cancers.

CEO: Manuel C. Alves Aivado

Telephone: +1 617 995-0900

Address: 490 Arsenal Way, Watertown 02472, MA, US

Number of employees: 13

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

67%33%

Bearish Bullish

64%36%

Bearish Bullish

56%44%

Bearish Bullish

60%40%

News

Stocktwits